Performance of Ceftazidime-Avibactam 30/20-μg and 10/4-μg Disks for Susceptibility Testing of Enterobacterales and Pseudomonas aeruginosa
Year: 2023
Type: article
Abstract: Multidrug-resistant Enterobacterales and P. aeruginosa strains have become a global public threat, with the emergence and prevalence of plasmid-mediated extended-spectrum β-lactamases (ESBLs), AmpC cephalosporinases, and carbapenemases disseminated worldwide. Ceftazidime-avibactam, which is commercially available, has shown excellent in vitro activity against multidrug-resistant and carbapenem-resistant Enterobacterales and P. aeruginosa isolates.
Source: Microbiology Spectrum
Authors: Renru Han, Siquan Shen, Dandan Yin, Li Ding, Qingyu Shi, Yang Yang, Yan Guo, Shi Wu, Peiyuan Zhi, Demei Zhu, Fupin Hu
Institutions: Fudan University, Huashan Hospital
Language: English
Subfield: Molecular Medicine
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,500
OpenAlex ID: W4319295365